Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the floor at ARM’s Meeting on the Med 2026 in Rome, this episode brings together leading voices from across cell and gene therapy to ask how companies, payers, and healthcare systems should think about pricing and reimbursement for therapies that may deliver long-term – and potentially life-changing – value.
As more one-time and potentially curative therapies reach patients, traditional reimbursement models are being put to the test. With many advanced therapies carrying high upfront costs, industry leaders argue that value must be assessed over a longer horizon – taking into account not only clinical outcomes, but also reduced hospitalizations, lower healthcare utilization, improved quality of life, and the broader societal benefits that can follow from durable treatment responses.
Featuring insights from Delara Motlagh of FUJIFILM Cellular Dynamics, Jason Foster of Ori Biotech, Alexa Crăciunescu of Autolomous, Louis Cicchini of Cencora, Miguel Forte of Kiji Therapeutics, Josh Ludwig of ScaleReady, Jon Alberdi Echeverria of VIVEbiotech, and Susan Nichols of Propel Biosciences, the discussion explores how the sector is rethinking access in an era of high-value therapies. From outcomes-based agreements and staged payments to clearer evidence generation and better communication with payers, the episode highlights the need for reimbursement models that better reflect the lasting impact these treatments can deliver.
Watch the video below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
